Skip to content
Eiu Logo Search Menu
  • Solutions
    Solutions
    • Healthcare GatewayData-driven intelligence for the healthcare industry
    • IVD GatewayTrack IVD market size, share and trends
    • Surgical GatewayInforming growth strategies for the surgical device sector
    • Browse all solutionsExplore all our products and services
  • Insights
    Insights
    • Clearstate insightsFrom recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed
    • White papersClearstate’s white papers provide practical business information on a wide range of topics, from macroeconomic events and country affairs to the latest industry trends
  • Careers
  • Contact
  • EIU Store
  • Search Search
  • Home
  • IVD Gateway
  • LabPRO Plus

Latest LabPRO Plus posts

Filters

Most-commonly tested cancer biomarkers using NGS in Europe: RAS, BRAF, EGFR

Most-commonly tested cancer biomarkers using NGS in Europe: RAS, BRAF, EGFR

Most-commonly tested cancer biomarkers using NGS in Europe…

Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5

Larger gene panels are the predominant NGS testing strategy in EU5

Larger gene panels are the predominant NGS testing strategy…

Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Precision medicine and access to NGS cancer biomarker testing in Europe

Precision medicine and access to NGS cancer biomarker testing in Europe

Precision medicine and access to NGS cancer biomarker…

Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Proportion of cancer biomarker testing done with NGS…

Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)

Economist Intelligence

  • EIU
  • Corporate Network
  • EIU Store
  • Careers

Help centre

  • Contact us
  • Tutorials

The Economist Group

  • The Economist Group
  • The Economist
  • The Economist Events
  • EIU Perspectives
  • EuroFinance
Follow EIU
Twitter Linkedin Facebook Youtube
  • Cookie policy
  • Terms of access
  • Privacy statement
  • Regulatory affairs
  • Licensing & Permissions
  • Manage cookies
© 2022 The Economist Intelligence Unit Limited. All rights reserved.